BDB -BiopanningDataSet Details

Biopanning Data

BiopanningDataSet ID: 3424

Peptides:

Sequences

CNARGDMHC(3)
CIVRGDNVC(3)
CTLRGDHHC(2)
CTIRGDTHC(2)
CNARGDAPC(2)
CVPRGDMHC(2)
CLRGDYPKC(1)
CECRGDCYC(1)
CRGDNTDQC(1)
CVSRGDQIC(1)
CVNRGDHSC(1)
CNGQNWRGC(1)
CLNGAYPNC(1)
CSLKGDLKC(1)
CSSSQSPVC(1)
CHNNHYRDC(1)
CHSTQMNHG(1)
CFGSKAGQC(1)
CHQTINRLC(1)
CDRADKQGC(1)
CTAATSTMC(1)
CQNPNQKFC(1)

Sequences Features:

Motif:

RGD

Unique Sequence Number:

Experimental Method:

Phage display (in vivo)

Sequencing Platform:

Sequencing Method:

Sanger sequencing

Rounds of Panning:

Reference:

PMID: 30730145

Target Name:

Blood

Template Name:

Not determined.

Structure of Target-Template Complex:

Not determined.

Structure of Target-Peptide Complex:

Not determined.

Library Name:

Ph.D.-C7C phage display library (CX7C)

Affinity Measurement Method:

Affinity Measurement Description:

Brief Description:

Briefly, Ph.D.-C7C phage library (1.0e11 plaque forming units, or pfu) in 300 μL saline was injected into the rat through the tail vein. Forty-eight hours later, as much blood as possible was collected from the heart and plated out on LB plates containing X-gal (5-bromo-4-chloro- 3-indolyl-b-Dgalactoside) and IPTG (isopropyl-b-D-thiogalactoside). About 300 blue plaques, obtained from six rats, were picked, mixed and amplified. After purification, 1.0e11 of the amplified phage was used for second round biopanning, following the same procedure as for the first round screening but with blood withdrawn at 96 h post injection. About 500 blue plaques obtained from the second round screening were mixed, amplified, and used for the third round screening, with blood withdrawn at 120 h post injection. Thirty blue plaques each from the second and third round screening were randomly picked and subjected to DNA sequencing.

BiopanningDataSet Comments:

The majority of the identified blood circulation-prolonging (BCP) peptides contained an arginine-glycine-aspartic acid (RGD) motif, which was necessary but insufficient for the circulation-prolonging activity. We further demonstrated that the RGD-mediated specific binding to platelets was primarily responsible for the enhanced blood retention of BCP1 (CNARGDMHC). The utility of the BCP1 peptide was demonstrated by fusion of the peptide to human heavy-chain ferritin (HFn), leading to significantly improved pharmacokinetic profile, enhanced tumor cell uptake and optimum anticancer efficacy for doxorubicin encapsulated in the HFn nanocage. Our results provided a proof-of-concept for an innovative yet simple strategy, which utilizes phage display to discover novel peptides with the capability of substantially prolonging blood circulation for engineered theranostic nanoparticles.

Curator:

Bifang He

Curation Date:

2019-05-28

First |

Prev |

3424

| Next

| Last